2018 Annual Meeting of the European Association for the Study of the Liver*

April 11-15, 2018; Paris, France
Review Capsules Summaries, download slides, and listen to audio commentary from expert-led Webinars covering critical studies on viral hepatitis and NAFLD/NASH from Paris.

Viral Hepatitis


96% SVR4 in noncirrhotic NS5A-experienced patients receiving 12-week, RBV-free regimen.

Released: April 18, 2018

Among 3 patients who relapsed without achieving SVR12, all had resistance associated substitutions.

Released: April 19, 2018

SVR12 rate of 96% in population where majority had ongoing drug use and/or were receiving opiate substitution therapy.

Released: April 20, 2018

Fewer relapses with inclusion of RBV, particularly in patients with baseline NS5A RAS.

Released: April 15, 2018

Overall SVR12 rate of 96% with no study drug–related serious adverse events at interim analysis.

Released: April 19, 2018

Patients also maintained HBV DNA suppression following switch from TDF to TAF.

Released: April 19, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Educational grant provided by:
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.